The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

September 8, 2023 updated by: Jin Geng, Nanjing Medical University
To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

Study Type

Observational

Enrollment (Estimated)

800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Jiangsu
      • Huai'an, Jiangsu, China, 223300
        • Recruiting
        • Huai'an First People's Hospital
        • Contact:
          • Xiaozhong Yang, MD.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with suspected coronary heart disease who experienced coronary angiography

Description

Inclusion Criteria:

  1. Patients with suspected coronary heart disease
  2. patients received coronary angiography

Exclusion Criteria:

  1. NYHA III-IV
  2. malignant tumor
  3. acute infection
  4. thyroid dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with suspected CHD who experienced CAG
Patients with suspected coronary heart disease who experienced coronary angiography
Other: No intervention
This is an obvertional study, and there is no intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
stenosis of coronary artery
Time Frame: 1 week
The stenosis of coronary artery based on the results of coronary angiography
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
coronary artery calcium
Time Frame: 1 week
The coronary artery calcification based on the results of coronary angiography
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nanjing Medical University

Investigators

  • Study Director: Ma Shuren, MD, NJMU

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Estimated)

October 31, 2023

Study Completion (Estimated)

December 31, 2023

Study Registration Dates

First Submitted

June 29, 2023

First Submitted That Met QC Criteria

July 13, 2023

First Posted (Actual)

July 14, 2023

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 8, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20230503

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Heart Disease, Susceptibility to, 1

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe